Concise review: Emerging concepts in clinical targeting of cancer stem cells

Stem Cells

Volumn 29, Issue 6, 2011, Pages 883-887

  Rasheed, Zeshaan A ^a   Kowalski, Jeanne ^b   Smith, B Douglas ^a   Matsui, William ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b EMORY UNIVERSITY   (United States)

Author keywords

Antineoplastic agents; Cancer stem cells; Drug resistance; Metastasis

Indexed keywords

ALPHA INTERFERON; CAPECITABINE; IMATINIB; LAPATINIB;

CANCER COMBINATION CHEMOTHERAPY; CANCER RELAPSE; CANCER STEM CELL; CANCER SURVIVAL; CELL FUNCTION; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL (TOPIC); DRUG WITHDRAWAL; HUMAN; MONOTHERAPY; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; SHORT SURVEY; TREATMENT RESPONSE;

ANIMALS; CLINICAL TRIALS AS TOPIC; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS; NEOPLASTIC STEM CELLS; TREATMENT OUTCOME;

EID: 79957622341     PISSN: 10665099     EISSN: None     Source Type: Journal    
DOI: 10.1002/stem.648     Document Type: Short Survey

References (55)

1. Bruce WR, Van Der Gaag H. A quantitative assay for the number of murine lymphoma cells capable of proliferation in vivo. Nature 1963;199:79-80.
2. Hamburger AW, Salmon SE. Primary bioassay of human tumor stem cells. Science 1977;197:461-463.
3. Park CH, Bergsagel DE, McCulloch EA. Mouse myeloma tumor stem cells: A primary cell culture assay. J Natl Cancer Inst 1971;46:411-422.
4. Lapidot T, Sirard C, Vormoor J et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 1994;367:645-648. (Pubitemid 24067706)
5. Wang JC, Lapidot T, Cashman JD et al. High level engraftment of NOD/SCID mice by primitive normal and leukemic hematopoietic cells from patients with chronic myeloid leukemia in chronic phase. Blood 1998;91:2406-2414. (Pubitemid 28155515)
6. Al-Hajj M, Wicha MS, Benito-Hernandez A et al. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 2003;100:3983-3988. (Pubitemid 36418143)
7. Ginestier C, Hur MH, Charafe-Jauffret E et al. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem cell 2007;1:555-567. (Pubitemid 350056407)
8. Goodell MA, Brose K, Paradis G et al. Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo. J Exp Med 1996;183:1797-1806. (Pubitemid 26134320)
9. Matsui W, Huff CA, Wang Q et al. Characterization of clonogenic multiple myeloma cells. Blood 2004;103:2332-2336. (Pubitemid 38326254)
10. Singh SK, Hawkins C, Clarke ID et al. Identification of human brain tumour initiating cells. Nature 2004;432:396-401. (Pubitemid 39551674)
11. Clarke MF, Dick JE, Dirks PB et al. Cancer stem cells - perspectives on current status and future directions: AACR Workshop on cancer stem cells. Cancer Res 2006;66:9339-9344. (Pubitemid 44623625)
12. Huff CA, Matsui W, Smith BD et al. The paradox of response and survival in cancer therapeutics. Blood 2006;107:431-434. (Pubitemid 43076361)
13. Burnett AK, Milligan D, Goldstone A et al. The impact of dose escalation and resistance modulation in older patients with acute myeloid leukaemia and high risk myelodysplastic syndrome: The results of the LRF AML14 trial. Br J Haematol 2009;145:318-332.
14. Lowenberg B, Ossenkoppele GJ, van Putten W et al. High-dose daunorubicin in older patients with acute myeloid leukemia. New Engl J Med 2009;361:1235-1248.
15. Koreth J, Cutler CS, Djulbegovic B et al. High-dose therapy with single autologous transplantation versus chemotherapy for newly diagnosed multiple myeloma: A systematic review and meta-analysis of randomized controlled trials. Biol Blood Marrow Transplant 2007;13:183-196. (Pubitemid 46112369)
16. Cunningham D, Chau I, Stocken DD et al. Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. J Clin Oncol 2009;27:5513-5518.
17. Moore MJ, Goldstein D, Hamm J et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: A phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007;25:1960-1966. (Pubitemid 46972777)
18. Boiko AD, Razorenova OV, van de Rijn M et al. Human melanoma-initiating cells express neural crest nerve growth factor receptor CD271. Nature 2010;466:133-137.
19. Quintana E, Shackleton M, Sabel MS et al. Efficient tumour formation by single human melanoma cells. Nature 2008;456:593-598.
20. Ishizawa K, Rasheed ZA, Karisch R et al. Tumor-initiating cells are rare in many human tumors. Cell Stem Cell 2010;7:279-282.
21. Matsui W, Wang Q, Barber JP et al. Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance. Cancer Res 2008;68:190-197. (Pubitemid 351380120)
22. Brennan SK, Meade B, Wang Q et al. Mantle cell lymphoma activation enhances bortezomib sensitivity. Blood. 2010;116:4185-4191.
23. Graham SM, Jorgensen HG, Allan E et al. Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood 2002;99:319-325.
24. Bao S, Wu Q, McLendon RE et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006;444:756-760. (Pubitemid 44949604)
25. Diehn M, Cho RW, Lobo NA et al. Association of reactive oxygen species levels and radioresistance in cancer stem cells. Nature 2009;458:780-783.
26. Dylla SJ, Beviglia L, Park IK et al. Colorectal cancer stem cells are enriched in xenogeneic tumors following chemotherapy. Plos One 2008;3:e2428.
27. Jimeno A, Feldmann G, Suarez-Gauthier A et al. A direct pancreatic cancer xenograft model as a platform for cancer stem cell therapeutic development. Mol Cancer Ther 2009;8:310-314.
28. Li X, Lewis MT, Huang J et al. Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J Natl Cancer Inst 2008;100:672-679.
29. Zeppernick F, Ahmadi R, Campos B et al. Stem cell marker CD133 affects clinical outcome in glioma patients. Clin Cancer Res 2008;14:123-129. (Pubitemid 351377986)
30. Rasheed ZA, Yang J, Wang Q et al. Prognostic significance of tumorigenic cells with mesenchymal features in pancreatic adenocarcinoma. J Natl Cancer Inst 2010;102:340-351.
31. -/low cells in breast cancer may not be associated with clinical outcome but may favor distant metastasis. Clin Cancer Res 2005;11:1154-1159.
32. Liu R, Wang X, Chen GY et al. The prognostic role of a gene signature from tumorigenic breast-cancer cells. New Engl J Med 2007;356:217-226. (Pubitemid 46143225)
33. Shipitsin M, Campbell LL, Argani P et al. Molecular definition of breast tumor heterogeneity. Cancer Cell 2007;11:259-273. (Pubitemid 46349843)
34. Pearce DJ, Taussig D, Zibara K et al. AML engraftment in the NOD/SCID assay reflects the outcome of AML: Implications for our understanding of the heterogeneity of AML. Blood 2006;107:1166-1173. (Pubitemid 43156319)
35. Laks DR, Masterman-Smith M, Visnyei K et al. Neurosphere formation is an independent predictor of clinical outcome in malignant glioma. Stem Cells 2009;27:980-987.
36. Bar EE, Chaudhry A, Lin A et al. Cyclopamine-mediated hedgehog pathway inhibition depletes stem-like cancer cells in glioblastoma. Stem Cells 2007;25:2524-2533. (Pubitemid 47582744)
37. Peacock CD, Wang Q, Gesell GS et al. Hedgehog signaling maintains a tumor stem cell compartment in multiple myeloma. Proc Natl Acad Sci USA 2007;104:4048-4053. (Pubitemid 47181576)
38. Zhao C, Chen A, Jamieson CH et al. Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukaemia. Nature 2009;458:776-779.
39. Fan X, Matsui W, Khaki L et al. Notch pathway inhibition depletes stem-like cells and blocks engraftment in embryonal brain tumors. Cancer Res 2006;66:7445-7452. (Pubitemid 44289197)
40. Brennan SK, Wang Q, Tressler R et al. Telomerase inhibition targets clonogenic multiple myeloma cells through telomere length-dependent and independent mechanisms. PLoS ONE 2010;5:e12487.
41. Marian CO, Cho SK, McEllin BM et al. The telomerase antagonist, imetelstat, efficiently targets glioblastoma tumor-initiating cells leading to decreased proliferation and tumor growth. Clin Cancer Res 2010;16:154-163.
42. Rudin CM, Hann CL, Laterra J et al. Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449. New Engl J Med 2009;361:1173-1178.
43. Von Hoff DD, Lorusso PM, Rudin CM et al. Inhibition of the hedgehog pathway in advanced basal-cell carcinoma. New Engl J Med 2009;361:1164-1172.
44. Gupta PB, Onder TT, Jiang G et al. Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell 2009;138:645-659.
45. Mani SA, Guo W, Liao M-J et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008;133:704-715. (Pubitemid 351636299)
46. Matsui W, Huff CA, Vala M et al. Anti-tumour activity of interferon-alpha in multiple myeloma: Role of interleukin 6 and tumor cell differentiation. Br J Haematol 2003;121:251-258. (Pubitemid 36560591)
47. Druker BJ, Guilhot F, O'Brien SG et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. New Engl J Med 2006;355:2408-2417. (Pubitemid 44903745)
48. Bonifazi F, de Vivo A, Rosti G et al. Chronic myeloid leukemia and interferon-alpha: A study of complete cytogenetic responders. Blood 2001;98:3074-3081.
49. Rousselot P, Huguet F, Rea D et al. Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years. Blood 2007;109:58-60. (Pubitemid 46053043)
50. Angstreich GR, Matsui W, Huff CA et al. Effects of imatinib and interferon on primitive chronic myeloid leukaemia progenitors. Br J Haematol 2005;130:373-381. (Pubitemid 43899585)
51. Bhatia R, Holtz M, Niu N et al. Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment. Blood 2003;101:4701-4707. (Pubitemid 36857723)
52. Burchert A, Muller MC, Kostrewa P et al. Sustained molecular response with interferon alfa maintenance after induction therapy with imatinib plus interferon alfa in patients with chronic myeloid leukemia. J Clin Oncol 2010;28:1429-1435.
53. Korkaya H, Paulson A, Iovino F et al. HER2 regulates the mammary stem/progenitor cell population driving tumorigenesis and invasion. Oncogene 2008;27:6120-6130.
54. Geyer CE, Forster J, Lindquist D et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. New Engl J Med 2006;355:2733-2743. (Pubitemid 46021510)
55. Huff C, Wang Q, Rogers K et al. Correlation of clonogenic cancer stem cell (CSC) growth with clinical outcomes in multiple myeloma (MM) patients undergoing treatment with high dose cyclophosphamide (Cy) and rituximab. AACR Meeting Abstr 2008;2008:LB-87.